Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Over the past decade, a growing body of evidence has strengthened the case for more effective treatment for P. vivax, particularly high-total-dose primaquine regimens and single-dose tafenoquine [5–7].”
From Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report (2026) · cites this paper as [6]
In the citing paper
“Tafenoquine administered as a single 300 mg dose has demonstrated strong protection against recurrence in multiple settings, including in Ethiopia [6, 7, 12].”
From Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report (2026) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 34
- Howes RE, Battle KE, Mendis KN, et al. Global epidemiology of Plasmodium vivax. Am J Trop Med Hyg 2016;95:Suppl:15-34.27402513 · DOI · Paper page
- 10.1186/1475-2875-13-321 · DOI
- 10.1186/1475-2875-10-355 · DOI · Paper page
- 10.1007/s11908-007-0021-4 · DOI · Paper page
- 10.1016/j.actatropica.2016.04.009 · DOI
- Galappaththy GN, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev 2013;10:CD004389-CD004389.24163057
- 10.1371/journal.pmed.1002299 · DOI · Paper page
- 10.1186/1475-2875-9-308 · DOI
- 10.1371/journal.pmed.1002379 · DOI · Paper page
- 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
- 10.1128/AAC.01588-16 · DOI
- 10.1371/journal.pmed.1001339 · DOI · Paper page
- 10.1073/pnas.1310402110 · doi:10.1073/pnas.1310402110
- Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine V: primaquine sensitivity as a manifestation of a multiple drug sensitivity. J Lab Clin Med 1981;97:750-759.7229509
- 10.4269/ajtmh.16-0779 · DOI · Paper page
- 10.1056/NEJMoa1802537 · DOI · Paper page
- 10.1093/infdis/jiv508 · DOI
- 10.1086/597303 · DOI · Paper page
- 10.1016/j.clinbiochem.2007.02.008 · DOI
- 10.1016/j.bcmd.2004.11.001 · DOI
- 10.1056/NEJMc1301936 · DOI · Paper page
- 10.1186/s12936-016-1145-5 · DOI
- 10.1038/sj.clpt.6100406 · DOI · Paper page
- 10.1002/bmc.1557 · doi:10.1002/bmc.1557
- 10.1590/0074-0276130579 · DOI
- 10.4269/ajtmh.2011.09-0723 · doi:10.4269/ajtmh.2011.09-0723
- 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
- 10.1371/journal.pone.0110691 · DOI
- 10.1186/1475-2875-12-212 · DOI · Paper page
- 10.1186/1475-2875-13-488 · DOI
- 10.1371/journal.pone.0160172 · DOI
- 10.1186/s12936-017-1784-1 · DOI · Paper page
- 10.1016/B978-0-12-397900-1.00002-5 · DOI · Paper page
- Kozenis (tafenoquine) approved by the Australian TGA for the radical cure of P. vivax malaria. Press release of GlaxoSmithKline September 21 2018 (http://au.gsk.com/en-au/media/press-releases/2018/kozenis-tafenoquine-approved-by-the-australian-tga-for-the-radical-cure-of-p-vivax-malaria/).
Cited by
Plasmodium vivax in the Era of the Shrinking P. falciparum Map
Price, R. N., Commons, R. J., Battle, K. E., Thriemer, K., & Mendis, K. (2020) · Trends in Parasitology · doi:10.1016/j.pt.2020.03.009 · Cited by 269
Antimalarial drug resistance in Africa: the calm before the storm?
Conrad, M. D., & Rosenthal, P. J. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30261-0 · Cited by 255
Varo, R., Chaccour, C., & Bassat, Q. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.05.024 · Cited by 31
Siegel, S. V., Trimarsanto, H., Amato, R., Murie, K., Taylor, A. R., Sutanto, E., Kleinecke, M., Whitton, G., Watson, J. A., Imwong, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51015-3 · Cited by 30
Self-citationDegaga, T. S., Sime, H., Ruybal-Pesántez, S., Osborne, A., Mwaura, M., Bamboro, S. A., Mnjala, H., Mekonnen, G., Ermias, S., Fantahun, A., et al. (2026) · Malaria Journal · doi:10.1186/s12936-026-06050-4 · Cited by 1
Metadata
- Authors
- Lacerda, M. V. G., Llanos-Cuentas, A., Krudsood, S., Lon, C., Saunders, D. L., Mohammed, R., Yilma, D., Batista Pereira, D., Espino, F. E. J., Mia, R. Z., Chuquiyauri, R., Val, F., Casapía, M., Monteiro, W. M., Brito, M. A. M., Costa, M. R. F., Buathong, N., Noedl, H., Diro, E., Getie, S., Wubie, K. M., Abdissa, A., Zeynudin, A., Abebe, C., Tada, M. S., Brand, F., Beck, H.-P., Angus, B., Duparc, S., Kleim, J.-P., Kellam, L. M., Rousell, V. M., Jones, S. W., Hardaker, E., Mohamed, K., Clover, D. D., Fletcher, K., Breton, J. J., Ugwuegbulam, C. O., Green, J. A., & Koh, G. C. K. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-17
- Volume
- 380
- Issue
- 3
- Pages
- 215-228
- ISSN
- 0028-4793
- 1533-4406
- Cited by
- 260
- References
- 0
- Language
- en
- Funders
- Medicines for Malaria Venture
- GlaxoSmithKline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. https://app.cochat.ai/papers/10.1056/nejmoa1710775
- The paper
- Lacerda, M. V. G., Llanos-Cuentas, A., Krudsood, S., Lon, C., Saunders, D. L., Mohammed, R., Yilma, D., Batista Pereira, D., Espino, F. E. J., Mia, R. Z., Chuquiyauri, R., Val, F., Casapía, M., Monteiro, W. M., Brito, M. A. M., Costa, M. R. F., Buathong, N., Noedl, H., Diro, E., . . . Koh, G. C. K. W. (2019). Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1710775
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.